Drug Information

Drug General Information
Drug ID
D0C3CF
Former ID
DIB003479
Drug Name
SDZ-NVI-085
Drug Type
Small molecular drug
Indication Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32] Discontinued in Phase 1 [544963]
Company
Novartis AG
Formula
C15H21NO2S
Canonical SMILES
c12c(C[C@@H]3[C@@H](C1)OCCN3C)c(ccc2SC)OC
CAS Number
CAS 104195-17-7
PubChem Compound ID
128503
Target and Pathway
Target(s) Alpha-1A adrenergic receptor Target Info Antagonist [534234]
KEGG Pathway Calcium signaling pathway
cGMP-PKG signaling pathway
Neuroactive ligand-receptor interaction
AMPK signaling pathway
Adrenergic signaling in cardiomyocytes
Vascular smooth muscle contraction
Salivary secretion
PANTHER Pathway Alpha adrenergic receptor signaling pathway
Reactome Adrenoceptors
G alpha (q) signalling events
G alpha (12/13) signalling events
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Endothelin Pathways
GPCR ligand binding
GPCR downstream signaling
AMPK Signaling
References
Ref 544963Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001726)
Ref 534234SDZ NVI 085, an alpha 1A-adrenoceptor agonist with 5-HT2A receptor antagonist properties. Eur J Pharmacol. 1996 Feb 15;297(1-2):83-6.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.